Anti-NMDA receptor (NMDAR) encephalitis is an acute disorder of the CNS caused by antibodies against the extracellular N-terminal domain of the receptor\'s NR1 subunit.^[@R1][@R2][@R3]^ Patients develop a severe neuropsychiatric syndrome with amnesia, behavioral changes, psychosis, dyskinesia, and epileptic seizures, and may also have hypoventilation and decreased consciousness.^[@R4]^ Eighty percent of patients recover well, achieving modified Rankin Scale (mRS) scores between 0 and 2, although many patients continue to have cognitive deficits, mostly in the form of memory and executive function impairment.^[@R5],[@R6]^ MRI appears normal in 25%--50% of patients with acute NMDAR encephalitis, but can show mild and transient T2/fluid-attenuated inversion recovery hyperintensities in the hippocampus, brainstem, and cerebral white and gray matter.^[@R7]^ In contrast, lasting functional and white matter brain changes, as well as persisting hippocampal damage associated with memory impairment, were observed recently in patients recovering from NMDAR encephalitis.^[@R8],[@R9]^

Retinal neurons express NMDAR, which are---among others---relevant for contrast sensitivity,^[@R10]^ and might be potential targets in acute NMDAR encephalitis. Specifically, mRNA for NMDAR subunits or functional NMDAR expression have been shown in horizontal cells,^[@R11],[@R12]^ amacrine cells,^[@R13][@R14][@R16]^ and ganglion cells in several vertebrates.^[@R13],[@R14],[@R17][@R18][@R22]^ Visual dysfunction is not among the common symptoms of acute NMDAR encephalitis; however, given the frequently severe presentation, visual symptoms might not attract attention or might be difficult to assess during the acute disease stage. Moreover, an overlap with demyelinating syndromes was recently described in a subgroup of patients with NMDAR encephalitis, many of them with visual deficits that were mostly caused by optic neuritis.^[@R23],[@R24]^ The objective of this study was to investigate the retina for potential structural damage after NMDAR encephalitis as well as potential visual function changes.

METHODS {#s1}
=======

Patients and controls. {#s1-1}
----------------------

For this cross-sectional observational study, patients post-recovery from the acute disease stage of NMDAR encephalitis were recruited from the outpatient clinic of the Department of Neurology of Charité-Universitätsmedizin Berlin. Inclusion criteria were diagnosis of previous NMDAR encephalitis and ability to give informed consent. Diagnosis was based on immunoglobulin G (IgG) NMDAR antibodies in patients\' CSF and characteristic clinical presentation. Residual clinical impairment was evaluated using the mRS.^[@R25]^ Two patients presented with a demyelinating overlap syndrome; both tested seronegative for aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies. Twenty-five patients had been included in previous studies investigating functional and structural MRI changes.^[@R8],[@R9]^ Healthy controls were randomly selected from the NeuroCure Clinical Research Center\'s research database and matched for age and sex.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

The study was approved by the internal ethics review board of the Charité-Universitätsmedizin Berlin and was conducted in conformity with the 1954 Declaration of Helsinki in its currently applicable version. All study participants gave informed written consent.

Visual function. {#s1-3}
----------------

Visual function testing was performed with Optec 6500 (Stereo Optical Inc., Chicago, IL). High-contrast visual acuity (VA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at simulated 20-feet distance. Low contrast sensitivity was measured using Functional Acuity Contrast Test (FACT) charts at photopic (85 cd) conditions at simulated 20 feet distance. FACT was performed at 5 different spatial frequencies. Contrast sensitivities were then combined as area under the curve (AUC) over all spatial frequencies, as previously described.^[@R26]^ All tests were performed monocularly for both eyes with habitual refractive error correction. One VA measurement from 1 eye and 3 FACT measurements from 3 eyes from 2 patients were not included in the analysis due to time constrains or technical issues.

Optical coherence tomography (OCT). {#s1-4}
-----------------------------------

Peripapillary retinal nerve fiber layer thickness (pRNFL) and macular volume scans were acquired with a Heidelberg Spectralis spectral-domain OCT (Heidelberg Engineering, Heidelberg, Germany) as previously described.^[@R27]^ pRNFL thickness was determined using the device\'s standard protocol from a 12° circular scan around the optic nerve head with activated eye tracker. The maximum 100 averaging frames in the automatic real-time mode (ART) were used whenever possible. Macular volume was acquired using a custom protocol focusing on the fovea (61 vertical slices \[B scans\], scanning angle of 30° × 25°, resolution 768 A scans per B scan, and ART 13). A second operator checked all scans for correct centering, sufficient signal strength, and segmentation based on the OSCAR-IB criteria.^[@R28]^ One patient had only 1 eye measured; 3 scans (2 pRNFL and 1 macular volume scan) from 3 patients, as well as 2 pRNFL scans from 2 healthy controls, did not pass quality control, leading to exclusion of these scans from data analysis.

Intraretinal segmentation data were taken from beta software (Heidelberg Eye Explorer V1.8.6.0 with Spectralis Viewing Module V6.0.0.2). This software automatically detects boundaries between retinal layers. All automated segmentation results were manually sighted and corrected where necessary by an experienced grader. After the intraretinal segmentation, the ganglion cell complex (GCC), consisting of retinal nerve fiber, ganglion cell, and inner plexiform layers, the inner nuclear layer (INL), the combined outer plexiform and nuclear layer (OPNL), and the photoreceptor layer (PRL) were analyzed as volume within the standard 6 mm ETDRS ring around the fovea.

Statistical analysis. {#s1-5}
---------------------

Data are presented as mean ± SD unless otherwise noted. OCT and visual function measurements were compared between patients with NMDAR encephalitis and healthy controls using generalized estimating equation (GEE) models with the respective OCT parameter from both eyes of each subject as dependent variable and group (healthy controls vs patients) as independent variable, correcting for age. GEE were also used to analyze a potential visual function association with mRS. Working correlation matrix was set to Exchangeable, accounting for within-subject intereye correlations. Age between groups was compared using a nonparametric Mann-Whitney *U* test. Statistical significance was achieved at *p* \< 0.05. No previous sample size calculation was performed and significance levels were not corrected for multiple comparisons. The study should therefore be considered exploratory. All statistical tests were performed with R Project 3.1.3 using package geepack 1.2-0.^[@R29]^

RESULTS {#s2}
=======

Thirty-one patients with NMDAR encephalitis (28 female/3 male, mean age 28.7 ± 8.9 years) were included in this study and compared to matched healthy controls (28 female/3 male, 28.6 ± 8.0 years). The sex match was exact; age did not differ between the groups (*p* = 0.889). Patients had a median mRS of 1 (range 0--3). Seventeen patients displayed no or only mild residual clinical impairment (mRS = 0 or 1), while 14 patients were clinically impaired (mRS ≥ 2). A detailed description of the mRS scores and treatment medication is given in [table 1](#T1){ref-type="table"}.

###### 

Detailed description of patients with NMDA receptor encephalitis

![](NEURIMMINFL2015007492TT1)

VA was reduced in patients with NMDAR encephalitis in comparison to matched healthy controls (logMAR 0.02 ± 0.14 vs −0.09 ± 0.14, *p* \< 0.001; [table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). Moreover, FACT was lower in patients (AUC 1.89 ± 0.21 vs 2.00 ± 0.26, *p* = 0.039; [table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). The mean scores of all 5 spatial frequencies (A--E) in FACT testing were decreased in patients compared to controls, but only the 3 highest frequencies (C--E) reached significance (A: *p* = 0.263, B: *p* = 0.404, C: *p* = 0.029, D: *p* \< 0.001, E: *p* = 0.014). Patients with no or only mild clinical impairment (mRS = 0 or 1, n = 17) performed better than patients with higher disability (mRS ≥ 2, n = 14) in high-contrast VA testing (logMAR −0.02 ± 0.11 vs 0.08 ± 0.17; GEE B = −0.10, SE = 0.05, *p* = 0.030), but there was no group difference in low-contrast FACT testing (*p* = 0.58).

###### 

Optical coherence tomography and visual function measurements

![](NEURIMMINFL2015007492TT2)

![Visual acuity differences\
(A) Visual acuity measured according to Early Treatment Diabetic Retinopathy Study charts and (B) low contrast sensitivity tested using Functional Acuity Contrast Test (FACT) charts at photopic (85 cd) conditions compared between healthy controls (HC) and patients with NMDA receptor encephalitis (NMDAR-E). Each dot represents 1 eye.](NEURIMMINFL2015007492FF1){#F1}

Patients and controls did not differ in retinal layer thickness measurements. Peripapillary RNFL, macular GCC, INL, OPNL, and PRL were all in the range of matched healthy controls ([table 2](#T2){ref-type="table"}, [figure 2](#F2){ref-type="fig"}).

![Optical coherence tomography differences\
(A) Mean thickness in μm of the peripapillary retinal nerve fiber layer (pRNFL) and the volume in mm^3^ of the macular (B) ganglion cell complex (GCC), (C) inner nuclear layer (INL), (D) outer plexiform and nuclear layer (OPNL), and (E) photoreceptor layer (PRL). HC = healthy controls; NMDAR-E = NMDA receptor encephalitis.](NEURIMMINFL2015007492FF2){#F2}

The 2 patients with overlapping demyelinating syndromes were not outliers in terms of high-contrast VA testing (case 1: logMAR both eyes = 0.1; case 2: logMAR right eye = 0.1 and logMAR left eye = −0.1) or in terms of low-contrast VA testing (case 1: AUC right eye = 1.58 and AUC left eye = 1.17; case 2: AUC both eyes = 2.15). Furthermore, statistical testing for OCT parameter differences remained negative after exclusion of both patients with overlapping demyelinating syndromes (data not shown).

DISCUSSION {#s3}
==========

We report mild reduction of high- and low-contrast VA in patients after NMDAR encephalitis, which---although still in the range of normative values---was lower than in matched healthy controls. Importantly, more severely affected patients had worse high-contrast VA than patients with good clinical recovery. In contrast, we observed no structural retinal damage.

This comprehensive assessment of visual function after NMDAR encephalitis complements recent reports on visual dysfunction in affected patients.^[@R30][@R31][@R32]^ A case report described severely reduced VA (20/125, right eye; 20/50, left eye) in a patient with NMDAR encephalitis that gradually normalized during recovery.^[@R32]^ This deficit was accompanied by impaired higher-order visual functions, e.g., reduced color sensation and face recognition. Impaired VA and optic neuritis were also reported in patients with NMDAR encephalitis and overlapping demyelinating syndromes.^[@R23],[@R24]^ Interestingly, antibodies to AQP4 and MOG were detected in most of these patients in addition to NMDAR antibodies. MOG antibodies were also found in a patient who had developed optic neuritis with optic disc swelling during NMDAR encephalitis relapse.^[@R31]^ While these latter studies observed visual impairment in patients with overlapping syndromes, we here report impaired VA in isolated NMDAR encephalitis without evidence of concomitant optic neuritis or other ophthalmic disease. Only 2 patients presented with a demyelinating overlap syndrome in our cohort, and both were seronegative for AQP4 and MOG antibodies.

Given the normal-appearing retinal structure in patients, we propose 2 candidate mechanisms for the underlying pathophysiology of the observed mild visual function loss. First, as several retinal neuron subtypes express NMDAR, the afferent visual system, including the retina, might be affected directly. mRNAs encoding NMDA subunits are expressed predominantly in the inner retina.^[@R33]^ In the INL, horizontal cells^[@R11],[@R12]^ and amacrine cells express NMDAR.^[@R13][@R14][@R16]^ Both cell types are interneurons, which integrate signals from photoreceptors before they are propagated to retinal ganglion cells. Moreover, ganglion cells have been shown to express functional NMDAR in several vertebrates.^[@R13],[@R14],[@R17][@R18][@R22]^ The above studies suggest a role of NMDAR in orchestrating the excitatory synapse and, more specifically, in modulating contrast sensitivity.^[@R10]^ In our study, all OCT retinal layer measurements were similar in patients and healthy controls, arguing against substantial structural damage or neurodegeneration of the retina. Arguably, functional changes could also be based on ultrastructural, synaptic alterations, which cannot be detected with OCT. This is in line with cerebral MRI analyses that show alterations of functional connectivity despite normal routine imaging.^[@R8]^ OCT only assesses retinal changes, but afferent visual system affection might reside anterograde, e.g., in the optic nerve, optic radiation, or primary visual cortex. Retrograde transsynaptic degeneration has been shown in diseases such as multiple sclerosis, meaning that substantial neurodegeneration would also present in the retina.^[@R34]^ Furthermore, a previous study employing structural and functional resting-state MRI of patients after NMDAR encephalitis did not report any macroscopic alterations in the visual cortex.^[@R8]^

Second, the visual function deficit perhaps does not result from alterations in the afferent visual pathway, but at least in part from cortical processing deficits during visual testing. The previously reported functional and structural changes in patients after NMDAR encephalitis that involve extensive white matter damage support this hypothesis.^[@R8]^ Furthermore, a previous study in patients with multiple sclerosis showed that cognitive function impairment is associated with visual test results beyond affection of the afferent visual pathway.^[@R35]^ The difference between patients with no or mild and those with existing residual clinical impairment supports that this might be at least partially the case in our study. Cognitive impairment might also influence test scores in other ways. For example, cognitively impaired patients might be less likely to regularly update refraction.

The study had several limitations. The visual system assessments presented in this study were part of a comprehensive test battery, including neuropsychological testing and MRI.^[@R8],[@R9]^ Due to the exploratory nature of this study, we were only able to include high-contrast VA and low-contrast sensitivity testing in addition to OCT and a basic neuro-ophthalmologic examination. To confirm and further elucidate the results of the study, electrophysiologic assessment of the optic nerve, tract, and radiation, as well as from the retina, would be necessary. Study participants only used habitual correction. As a result, we cannot rule out a potential bias introduced by insufficient refractory error correction. However, data distribution of high- and low-contrast FACT measurements and the reduction of all 5 spatial frequencies in low-contrast testing suggests that a potential refractory error bias could not sufficiently explain observed group differences. For low-contrast VA, further studies are needed to determine the extent to which deficits are caused either by high-contrast acuity deficits or affection of low-contrast visual perception. None of the patients reported visual dysfunction, and the reported mild VA deficits seem not to be relevant for an individual patient and instead were only statistically significant in a group comparison. The clinical relevance of visual function deficits---beyond insight into the pathophysiology of the disease---therefore remains to be investigated.

In this study, we present preliminary evidence for visual dysfunction in patients recovering from NMDAR encephalitis. These functional changes were not based on detectable structural damage using OCT. The association between visual function and residual disability indicates that visual function may provide insight into general disease processes in NMDAR encephalitis. Potentially, visual function examination may provide information to the clinician about underlying changes in disease activity when performed longitudinally. Therefore, clarifying the clinical significance of visual dysfunction in NMDAR encephalitis warrants further investigation, including in longitudinal studies. Additionally, future studies should include electroretinography to assess potential functional retinal alterations.
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